GR1803 injection for patients with relapsed/refractory multiple myeloma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and efficacy of GR1803 injection in patients diagnosed with relapsed or refractory multiple myeloma complicated by extramedullary plasmacytoma. Participants will receive the injection until they experience intolerable toxicity, disease progression, or for a maximum of two years. The study aims to assess how well this treatment works in managing the disease and improving patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1、ECOG score 0-2 2、≥18 years of age 3、Multiple myeloma must be Complicated by Extramedullary Plasmacytoma.

Exclusion Criteria:

* 1、Prior treatment with any BCMA-targeted therapy 2、Known active CNS involvement or exhibits clinical signs of meningeal involvement of multiple myeloma 3、Known allergies, hypersensitivity, or intolerance to the study drug (teclistamab) or its excipients 4、Plasma cell leukemia , Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary amyloid light-chain amyloidosis.

Where it's running

• Institute of Hematology & Blood Diseases Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: Gang An, PhD
• Email: angang@ihcams.ac.cn
• Phone: +8613502181109

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating XEMBIFY® with standard treatment to prevent infections in patients with certain blood cancers

  This study is testing if adding XEMBIFY® to standard treatment can help prevent serious infections in adults with certain blood cancers.

  Recruiting at 56 sites Phase 3 Grifols Therapeutics LLC · Bullhead City, Arizona and 61 other locations · NCT05645107

• GR1803 injection versus daratumumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma

  This trial tests whether GR1803 injection works better than daratumumab combined with pomalidomide and dexamethasone for adults with relapsed or refractory multiple myeloma who have had one to three prior treatments.

  Recruiting Phase 3 Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Tianjin · NCT07452198

• GR1803 for systemic lupus erythematosus (SLE)

  This trial will test GR1803 injections in people with active systemic lupus (SLE) to see if the drug is safe and helps control lupus symptoms.

  Recruiting Phase 1/2 Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Wuhan, Hubei · NCT07348055

• GR2303 injection safety and immune response in healthy adults

  This trial will try GR2303 injections in healthy adults to see if they are safe and how the body handles them and responds immunologically.

  Recruiting Phase 1 Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07199270

• IL4Rα antibody for seasonal allergic rhinitis (hay fever)

  This trial will test whether injections of an IL4Rα monoclonal antibody help people with seasonal allergic rhinitis (hay fever) who haven't been well controlled with nasal steroids.

  Recruiting Phase 3 Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Wuhan, Hubei · NCT07154342

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.